/ EN

Online Contract Signing Ceremony: Xi'an Yufan Biotechnology plans to invest 100 million Yuan to build a CAR-T cell manufacturing facility

On Feb 22, 2020, a contract signing ceremony of Xi 'an Biomedical Industry Cluster Group was held in Xi 'an High-tech District. To ensure the safety of participants during the pandemic, the contract signing was carried out via a special online ceremony, changing the way of contract signing from "face to face" to "screen to screen".

MingMed Biotechnology Opening Ceremony

In the afternoon of April 19, 2020, Guangzhou MingMed Biotechnology Co., Ltd. held its Opening Ceremony.

Yufan Biotechnologies and Abound Bio Sign Multi-Year Agreement to Develop Next Generation CAR T-cell Therapies for Cancer

PITTSBURGH, Sept.16,2020 /PRNewswire/-- ExhaustionofT-cellsisakeyreasonwhyCART-celltherapymayfailtocontrolcancer. Recentworkledby XuebinLiao,PhD,ProfessorofPharmaceuticalScienceatTsinghuaUniversity(Si

Yufan Bio Partners with Pittsburgh's Abound to Develop Novel CAR-T Therapies

YufanBio,a Xi'an clinical-stageCAR-Tcompany,partneredwithAboundBioofPittsburghtodevelopnovelCAR-Ttechnologies.ThetwocompanieswillexploretheuseofHPK1(hematopoieticprogenitorkinase1)inhibitorstomakeCAR-
Previous page

Home   丨   About Us   丨   Product and Pipeline   丨   Our Team   丨   News   丨   Career   丨   Contact

Address: 106 Fengze East Road, Nansha District, Guangzhou 
Email: ming-med@ming-med.com

Copyright © 2020 ming-med.com  保留所有权利  粤ICP备20029450号-1